Fortrea Holdings Inc. (FTRE)
| Market Cap | 2.12B +91.9% |
| Revenue (ttm) | 2.67B -3.4% |
| Net Income | -68.70M |
| EPS | -0.73 |
| Shares Out | 96.50M |
| PE Ratio | n/a |
| Forward PE | 23.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,941,806 |
| Open | 20.46 |
| Previous Close | 20.46 |
| Day's Range | 20.14 - 22.12 |
| 52-Week Range | 8.55 - 26.16 |
| Beta | 1.86 |
| Analysts | Buy |
| Price Target | 23.63 (+7.61%) |
| Earnings Date | Oct 29, 2026 |
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, ... [Read more]
Financial Performance
In 2025, Fortrea Holdings's revenue was $2.72 billion, an increase of 1.00% compared to the previous year's $2.70 billion. Losses were -$986.20 million, 200.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for FTRE stock is "Buy." The 12-month stock price target is $23.63, which is an increase of 7.61% from the latest price.
News
Fortrea price target raised to $26 from $23 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on Fortrea (FTRE) to $26 from $23 and keeps a Buy rating on the shares. The firm updated its model…
Fortrea price target raised to $28 from $25 at Evercore ISI
Evercore ISI raised the firm’s price target on Fortrea (FTRE) to $28 from $25 and keeps an Outperform rating on the shares.
Fortrea price target raised to $27 from $22 at Citi
Citi raised the firm’s price target on Fortrea (FTRE) to $27 from $22 and keeps a Buy rating on the shares.
Fortrea price target raised to $26 from $24 at Baird
Baird raised the firm’s price target on Fortrea (FTRE) to $26 from $24 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results. Published…
Barclays ups Fortrea target, says buy the selloff
Barclays raised the firm’s price target on Fortrea (FTRE) to $26 from $23 and keeps an Overweight rating on the shares. The firm recommends buying the post-earnings selloff in the…
Fortrea Holdings Earnings Call Transcript: Q3 2026
Q3 delivered $691.5M revenue, $58M adjusted EBITDA and 1.12x book-to-bill, with stronger margins and cash flow. FY2026 guidance was raised, while demand recovery and the early-phase acquisition support growth plans.
Fortrea Holdings Earnings release: Q3 2026
Fortrea Holdings released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Fortrea Holdings Slides: Q3 2026
Fortrea Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Fortrea Holdings Quarterly report: Q3 2026
Fortrea Holdings has published its Q3 2026 quarterly earnings report on October 29, 2026.
Fortrea reports Q3 adjusted EPS 28c, consensus 22c
Reports Q3 revenue $691.5M, consensus $671.52M. “Fortrea (FTRE) delivered another quarter of progress on our return-to-growth strategy, reflecting stronger commercial execution, continued operational ...
Fortrea Reports Third Quarter 2026 Results
Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Sustained commercial momentum, continued margin improvement, and targeted investments...
Fortrea to Participate in Jefferies Global Healthcare Conference
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP o...
Fortrea, Omico announce collaboration to accelerate precision oncology research
Fortrea (FTRE) and Omico announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarker-matched clinical trials. By combining Omico’s precision onc...
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-mat...
Fortrea price target raised to $24 from $22 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Fortrea (FTRE) to $24 from $22 and keeps a Neutral rating on the shares.
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-be...
Deutsche upgrades Fortrea to Buy on ‘fundamental inflection point’
Deutsche Bank upgraded Fortrea (FTRE) to Buy from Hold with a price target of $25, up from $20. The company is at a “fundamental inflection point” with better prospects for…
Fortrea upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Fortrea (FTRE) to Buy from Hold with a $25 price target
Fortrea price target raised to $15.50 from $13 at BofA
BofA analyst Avantika Dhabaria raised the firm’s price target on Fortrea (FTRE) to $15.50 from $13 and keeps an Underperform rating on the shares. The life science tools sector has…
Fortrea upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Fortrea (FTRE) to Overweight from Equal Weight with a price target of $23, up from $22. The firm believes Fortrea is the only contract research organization with margin…
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter ...
Fortrea initiated with a Neutral at UBS
UBS analyst Kevin Caliendo initiated coverage of Fortrea (FTRE) with a Neutral rating and $22 price target The firm sees low visibility into the company’s revenue inflection. Fortrea could fall…
Fortrea Holdings Transcript: 2026 Global Healthcare Conference
Leadership is driving growth through strategic acquisitions, expanding clinical pharmacology capacity, and prioritizing higher-margin business. Margins are targeted to reach mid-teens in 3-5 years, with operational leverage expected as service revenue grows. AI initiatives are underway, with industry-wide impact anticipated in 1-2 years.
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of...
Fortrea to Participate in September Investor Conferences
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP ...